ABSTRACT
Background and Objective: The prevalence of aspirin resistance amongst patients with cardiovascular disease and in the healthy population has been reported to range from 5% to 45%. Lately, rapid platelet function analyzer (RPFA) a point-of-care determination of platelet aggregability has been introduced for rapid determination of aspirin resistant patients. The purpose of this paper is to report the prevalence of aspirin resistance among patients with recurrent non cardioembolic ischemic stroke as detected by RPFA (Ultegra®). Methods: Seventy-seven patients with mean age of 61.2 + 10.4 (range 33-87 years) who developed recurrent non-cardioembolic ischemic stroke were consecutively included in the study. Fifty-seven (74%) were males. Aspirin resistance was determined using the RPFA (Ultegra®) machine. Patients with an aspirin reaction unit (ARU) value above 550 were identified as aspirin resistant. Results: Following this method, the prevalence of aspirin resistance was determined to be 10.4% (95% CI: 1% to17%). Comparison of baseline characteristics between aspirin resistant and aspirin responsive patients did not show any significant difference. Conclusion: The prevalence of aspirin resistance in this study was 10.4% amongst patients with recurrent non-cardioembolic ischemic stroke. The study has shown the feasibility of utilizing RPFA (Ultegra®) machine in detecting aspirin resistance.